

9. Adams H, Chaichana KL, Avendaño J, Liu B, Raza SM, et al. Adult Cerebellar Glioblastoma: Understanding Survival and Prognostic Factors Using a Population- Based Database from 1973 to 2009. *World Neurosurg.* 2013;80(6):237–43.
10. Korja M, Raj R, Seppa K, et al. Glioblastoma survival is improving despite incidence rates: a nationwide study between 2000 and 2013 in Finland. *Neuro Oncol.* 2019;21:370–9.

I. Rouco Axpe^{a,*}, B. Mateos Goñi^b, L. Zaldumbide Dueñas^c, E. Fernández-Lomana Idiondo^c

^a *Consulta de Ataxias, Servicio de Neurología, Hospital Universitario de Cruces, Barakaldo, Bizkaia, Spain*

^b *Servicio de Neurorradiología, Hospital Universitario de Cruces, Barakaldo, Bizkaia, Spain*

^c *Servicio de Anatomía Patológica, Hospital Universitario de Cruces, Barakaldo, Bizkaia, Spain*

* Corresponding author.

E-mail address: idoia.roucoaxpe@osakidetza.eus (I. Rouco Axpe).

<https://doi.org/10.1016/j.nrleng.2020.04.020>
2173-5808/

© 2020 Sociedad Española de Neurología. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Muscle weakness, joint laxity and keloids. A more than suggestive association[☆]



Debilidad muscular, laxitud articular y queloides. Una asociación más que sugerente

Dear Editor:

Collagen VI (ColVI)—related myopathies encompass a group of diseases ranging from milder muscle disorders, such as Bethlem myopathy, to more severe forms, such as Ullrich congenital muscular dystrophy.^{1–4} From a phenotypic viewpoint, these disorders are characterised by muscle weakness, joint contractures in flexion, joint hypermobility predominantly affecting distal joints, and skin alterations (follicular hyperkeratosis, “velvety” skin, and keloid scars). Collagen VI is a structural protein of the extracellular matrix, comprising 3 subunits, encoded by the genes *COL6A1*, *COL6A2*, and *COL6A3*. Although new mutations in these genes are constantly being reported,⁵ establishing a genotype-phenotype correlation is challenging due to the clinical heterogeneity and genetic overlaps.^{6,7}

We present the case of a 58-year-old man with history of early-onset, slowly progressing limb-girdle muscular dystrophy associated with respiratory involvement and no known genetic defects. Diagnosis had been established when the patient was 2 years old due to delayed acquisition of developmental milestones; weakness predominantly affected distal muscles, and a muscle biopsy revealed signs compatible with muscular dystrophy. At the time of assessment at our department, the patient presented proximal muscle weakness but did not require support to walk. The examination revealed 4/5 muscle strength at the level of the shoulder and pelvic girdles, joint hypermobility predominantly in the hands (Fig. 1B), con-

tractures in the metacarpophalangeal and interphalangeal joints (Fig. 1A), and keloid scars in the area where the muscle biopsy specimen was taken (Fig. 1C). From a respiratory viewpoint, the patient presented a pattern of moderate restrictive pulmonary function,⁸ with complementary tests revealing no cardiac alterations. He also presented increased creatine kinase levels ($\times 2$). A muscle MRI scan was performed to confirm suspicion of ColVI-related myopathy and to guide the genetic study. The MRI scan (Fig. 1D) showed a pattern compatible with ColVI-related myopathy, and a genetic study revealed that the patient was a heterozygous carrier of variant p.Gly289Val in the gene *COL6A2* (reference sequence: NM_001849.3:c.866G>T NC_000021.8:g.47535933G>T); this finding is compatible with diagnosis of Bethlem myopathy. This mutation causes an amino acid change involving glycine at position 289 of the α_2 chain of collagen VI, which forms part of the Gly-X-Y motif in the N-terminal region of the triple helical domain of the protein, with this amino acid being substituted by valine. This missense mutation was classified as probably pathogenic in the EmVClass catalogue, but had not been listed in any other genetic database, nor had it been reported in previous publications. However, our patient’s clinical characteristics and muscle MRI findings support the pathogenic nature of the mutation. A family segregation study did not identify the mutation in our patient’s parents, meaning that the mutation was de novo.

We present a case of Bethlem myopathy secondary to a novel *COL6A2* mutation (c.866G>T, p.Gly289Val); this mutation had not previously been described as pathogenic in the literature. ColVI-related myopathy should be suspected in patients with predominantly proximal muscle weakness and distal joint hypermobility, distal muscle contractures, and skin alterations (typically keloids). Muscle MRI reveals a characteristic pattern,⁹ and diagnosis can be confirmed with genetic studies, although a clear genotype-phenotype correlation cannot be established.

From a genetic viewpoint, Ullrich congenital muscular dystrophy has typically been reported to follow an autosomal recessive inheritance pattern, whereas Bethlem myopathy is thought to follow an autosomal dominant pattern. However, both inheritance patterns have been described in the spectrum of ColVI-related myopathies.^{5,10–13} Genetic sequencing enables analysis of

[☆] Please cite this article as: Martínez-Martín Á, Díaz-Maroto Cicuéndez I, Simón Sánchez J, García-García J. Debilidad muscular, laxitud articular y queloides. Una asociación más que sugerente. *Neurología.* 2021;36:243–245.




Figure 1 (A) Contractures affecting the metacarpophalangeal and interphalangeal joints. (B) Joint hypermobility. (C) Keloid scar in the area where a muscle biopsy specimen was taken. (D) Lower-limb MRI scan showing a pattern compatible with ColVI-related myopathy: fatty degeneration in the periphery of the vastus lateralis muscles (yellow arrows) and in the periphery and anterior-central area of the rectus femoris muscles, with a U-shaped pattern (red arrows).

exonic mutations in *COL6A1*, *COL6A2*, and *COL6A3*. Missense mutations, like the one identified in our patient, usually appear de novo in heterozygosis, exerting a dominant-negative effect. More specifically, missense mutations in the Gly-X-Y motif in the N-terminal region of the triple helical domain of collagen VI constitute the most frequent cause of ColVI-related myopathies.¹¹ Lastly, 3 other pathogenic variants are reported to involve the same amino acid residue: c.865G>T, p.Gly289Arg¹⁴; c.865G>T, p.Gly289Cys¹⁴; and c.866G>A, p.Gly289Asp (the latter is included in the ClinVar database).

Conflicts of interest

The authors have no conflicts of interest to declare.

References

1. Bönnemann CG. The collagen VI-related myopathies: Ullrich congenital muscular dystrophy and Bethlem myopathy. *Handb Clin Neurol.* 2011;101:81–96.
2. Demir E, Sabatelli P, Allamand V, Ferreiro A, Moghadaszadeh B, Makrelouf M, et al. Mutations in *COL6A3* cause severe and mild phenotypes of Ullrich congenital muscular dystrophy. *Am J Hum Genet.* 2002;70:1446–58.

3. Demir E, Ferreiro A, Sabatelli P, Allamand V, Makri S, Echenne B, et al. Collagen VI status and clinical severity in Ullrich congenital muscular dystrophy: phenotype analysis of 11 families linked to the COL6 loci. *Neuropediatrics*. 2004;35:103–12.
4. Mercuri E, Yuva Y, Brown SC, Brockington M, Kinali M, Jungbluth H, et al. Collagen VI involvement in Ullrich syndrome: a clinical, genetic, and immunohistochemical study. *Neurology*. 2002;58:1354–9.
5. Scacheri PC, Gillanders EM, Subramony SH, Vedanarayanan V, Crowe CA, Thakore N, et al. Novel mutations in collagen VI genes: expansion of the Bethlem myopathy phenotype. *Neurology*. 2002;58:593–602.
6. Panadés-de Oliveira L, Rodríguez-López C, Cantero Montenegro D, Marcos Toledano MDM, Fernández-Marmiesse A, Esteban Pérez J, et al. Bethlem myopathy: a series of 16 patients and description of seven new associated mutations. *J Neurol*. 2019;266:934–41.
7. Kim SY, Kim WJ, Kim H, Choi SA, Lee JS, Cho A, et al. Collagen VI-related myopathy: expanding the clinical and genetic spectrum. *Muscle Nerve*. 2018;58:381–8.
8. Foley AR, Quijano-Roy S, Collins J, Straub V, McCallum M, Deconinck N, et al. Natural history of pulmonary function in collagen VI-related myopathies. *Brain*. 2013;136:3625–33.
9. Morrow JM, Pitceathly RD, Quinlivan RM, Yousry TA. Muscle MRI in Bethlem myopathy. *BMJ Case Rep*. 2013;2013, bcr2013008596.
10. Gualandi F, Urciuolo A, Martoni E, Sabatelli P, Squarzone S, Bovolenta M, et al. Autosomal recessive Bethlem myopathy. *Neurology*. 2009;73:1883–91.
11. Suárez B, Lozano-Arango A, Araneda D, Cortés F, Hervias C, Calcagno G, et al. Collagen VI related myopathies. When to suspect, how to identify. The contribution of muscle magnetic resonance. *Rev Chil Pediatr*. 2018;89:399–408.
12. Merlini L, Martoni E, Grumati P, Sabatelli P, Squarzone S, Urciuolo A, et al. Autosomal recessive myosclerosis myopathy is a collagen VI disorder. *Neurology*. 2008;71:1245–53.
13. Foley AR, Hu Y, Zou Y, Columbus A, Shoffner J, Dunn DM, et al. Autosomal recessive inheritance of classic Bethlem myopathy. *Neuromuscul Disord*. 2009;19:813–7.
14. Briñas L, Richard P, Quijano-Roy S, Gartioux C, Ledeuil C, Lacène E, et al. Early onset collagen VI myopathies: genetic and clinical correlations. *Ann Neurol*. 2010;68:511–20.

Á. Martínez-Martín^{a,*}, I. Díaz-Maroto Cicuéndez^a, J. Simón Sánchez^b, J. García-García^a

^a Servicio de Neurología, Complejo Hospitalario Universitario de Albacete, Albacete, Spain

^b Departamento Clínico - Área de Neurología, Health in Code S.L., A Coruña, Spain

* Corresponding author.

E-mail address: alvaro.martnmd@gmail.com (Á. Martínez-Martín).

<https://doi.org/10.1016/j.nrleng.2020.05.018>
2173-5808/

© 2020 Sociedad Española de Neurología. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

25(OH)D₃ deficit and multiple sclerosis: A simple epidemiological association or a true causal relationship[☆]



Déficit de 25-OH-D₃ y esclerosis múltiple: una simple asociación epidemiológica o una verdadera relación de causalidad

Dear Editor:

Vitamin D deficiency is a true epidemic. Epidemiological studies indicate that the condition is more frequent above the 40th parallel north.¹ In humans, vitamin D is mainly synthesised in the dermis through the action of ultraviolet B radiation, which catalyses the photoconversion of 7-dehydrocholesterol to cholecalciferol; after hepatic hydroxylation, cholecalciferol is converted to 25-hydroxyvitamin D₃ (25-OH-D₃) or calcifediol, which is the most abundant form of vitamin D₃ in the human body but is not biologically active. Subsequently, 25-OH-D₃ undergoes hydroxylation by 1- α -hydroxylase in the kidneys, forming the active metabolite 1,25-dihydroxyvitamin D₃, also known as 1,25(OH)₂D₃ or calcitriol. This metabolite acts by binding to vitamin D receptors. Vitamin D receptors located

in cell nuclei trigger so-called genomic actions, leading to protein synthesis, and non-genomic (rapid) actions, such as the induction of second messengers and the opening of ion channels.^{2,3}

Various epidemiological studies have identified an association between low levels of 25-OH-D₃ and multiple sclerosis (MS).^{3,4} It has also been reported that 25-OH-D₃ deficiency is associated with radiological disease activity, defined as the presence of new lesions on T2-weighted MRI sequences or contrast-enhancing lesions.⁵ Finally, other studies indicate that vitamin D supplementation has a beneficial effect on these radiological parameters.⁶ The biological plausibility of this association may be explained by a tolerogenic environment promoted by the anti-inflammatory and immunomodulatory effects of vitamin D.^{3,7}

A recent epidemiological study on the prevalence of MS in the Spanish city of Ourense (latitude, 42° 34' N) recorded the highest rate reported to date in the Iberian Peninsula: 184 cases/100 000 population, approaching the figures recorded in more northerly countries with Anglo-Saxon influences. One mechanism favouring MS may be the presence of vitamin D deficiency, which is recorded in over 95% of patients with MS.⁸ In the general population, 25-OH-D₃ deficiency is defined as levels < 14 ng/mL, with levels between 15 and 29 ng/mL considered to indicate insufficiency. Our laboratory's reference values for the active metabolite calcitriol are between 20 and 55 pg/mL.

We decided to analyse 1,25(OH)₂D₃ in our population of patients with MS, determining levels in a randomised sample of 44 individuals. Median plasma levels were 15 ng/mL (range, 8–36) for calcifediol and 46.5 pg/mL (22–83) for cal-

[☆] Please cite this article as: García Estévez DA. Déficit de 25-OH-D₃ y esclerosis múltiple: una simple asociación epidemiológica o una verdadera relación de causalidad. *Neurología*. 2021;36:245–246.